Effects of raloxifene on platelet functions in patients with postmenopausal osteoporosis

Platelets

Volumn 17, Issue 6, 2006, Pages 351-353

  Ertugrul, Derun Taner ^a   Gürsoy, Alptekin ^a   Yücel, Muammer ^a   Sahin, Mustafa ^a   Unal, Asli Dogruk ^a   Pamuk, Baris ^a   Berberoglu, Zehra ^a   Aytürk, Semra ^a   Tutuncu, Neslihan Bascil ^a   Demirag, Nilgun Guvener ^a  

^a BASKENT UNIVERSITY   (Turkey)

Author keywords

Closure time; Function; Osteoporosis; PFA 100; Platelets; Raloxifene

Indexed keywords

RALOXIFENE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG EFFECT; HUMAN; MEDICAL PRACTICE; MEDICAL RESEARCH; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; THROMBOCYTE FUNCTION;

AGED; BLOOD PLATELETS; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PLATELET FUNCTION TESTS; POSTMENOPAUSE; PROSPECTIVE STUDIES; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; STATISTICS, NONPARAMETRIC;

EID: 33748803602     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.1080/09537100600746649     Document Type: Article

References (12)

1. Cosman F, Lindsay R. Selective estrogen receptor modulators: Clinical spectrum. Endocr Rev 1999;20:418-434.
2. Brzozowski AM, Pike AC, Dauter Z, Hubbard RE, Bonn T, Engstrom O, et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 1997;389:753-758.
3. Lonard DM, Smith CL. Molecular perspectives on selective estrogen receptor modulators (SERMs): Progress in understanding their tissue-specific agonist and antagonist actions. Steroids 2002;67:15-24.
4. Jayachandran M, Miller VM. Human platelets contain estrogen receptor alpha, caveolin-1 and estrogen receptor associated proteins. Platelets 2003;14:75-81.
5. Khetawat G, Faraday N, Nealen ML, Vijayan KV, Bolton E, Noga SJ, Bray PF. Human megakaryocytes and platelets contain the estrogen receptor beta and androgen receptor (AR): Testosterone regulates AR expression. Blood 2000;95:2289-2296.
6. Azevedo GD, Franco RF, Baggio MS, Maranhao TM, Ferriani RA, Silva de Sa MF. Effects of raloxifene therapy on the anticoagulant system in postmenopausal women. Climacteric 2003;6:140-145.
7. Cosman F, Baz-Hecht M, Cushman M, Vardy MD, Cruz JD, Nieves JW, et al. Short-term effects of estrogen, tamoxifen and raloxifene on hemostasis: A randomized-controlled study and review of the literature. Thromb Res 2005;116:1-13.
8. Kundu SK, Heilmann EJ, Sio R, Garcia C, Davidson RM, Ostgaard RA. Description of an in vitro platelet function analyzer-PFA-100. Semin Thromb Hemost 1995;21(Suppl 2):106-112.
9. Franchini M. The platelet function analyzer (PFA-100): An update on its clinical use. Clin Lab 2005;51:367-372.
10. Jayachandran M, Mukherjee R, Steinkamp T, LaBreche P, Bracamonte MP, Okano H, et al. Differential effects of 17beta-estradiol, conjugated equine estrogen, and raloxifene on mRNA expression, aggregation, and secretion in platelets. Am J Physiol Heart Circ Physiol 2005;288:2355-2362.
11. O'Lone R, Frith MC, Karlsson EK, Hansen U. Genomic targets of nuclear estrogen receptors. Mol Endocrinol 2004;18:1859-1875.
12. Nilsson S, Koehler KF. Oestrogen receptors and selective oestrogen receptor modulators: Molecular and cellular pharmacology. Basic Clin Pharmacol Toxicol 2005;96:15-25.